Step Pharma SAS
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Holding
- Established
- 2014-06-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.step-ph.com
Clinical Trials
3
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)A Phase 1 Study to Assess STP938 as a Monotherapy in Adults With High Risk Essential Thrombocythaemia
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Step Pharma, SAS
- Target Recruit Count
- 20
- Registration Number
- NCT06786234
- Locations
- 🇫🇷
CHU Brest, Brest, France
🇫🇷Institut Paoli-Calmettes, Marseille, France
🇫🇷CHU Nantes, Nantes, France
Study of STP938 in Advanced Solid Tumours
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Step Pharma, SAS
- Target Recruit Count
- 70
- Registration Number
- NCT06297525
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, Paris, France
🇺🇸Comprehensive Hematology Oncology, LLC, Saint Petersburg, Florida, United States
🇺🇸Mary Crowley Cancer Research Center, Dallas, Texas, United States
A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Step Pharma, SAS
- Target Recruit Count
- 180
- Registration Number
- NCT05463263
- Locations
- 🇺🇸
Memorial Sloan Kettering, New York, New York, United States
🇫🇷Hôpital Saint-Louis, Paris, France
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
News
No news found